Patent ID: 8314091

Claim:
A N-benzyl,N′-arylcarbonylpiperazine derivative having the general formula I wherein n is 1 or 2; A is a 6-membered aromatic ring optionally containing 1 or 2 nitrogen atoms; X is NR 8 , O or a bond; R 1 is H, (C 1-8 )alkyl optionally substituted with halogen, (C 1-4 )alkyloxy, (C 1-4 )alkyloxycarbonyl, (C 3-8 )cycloalkyl, OH, CF 3 , cyano or NR 9 R 10 , (C 2-6 )alkenyl, (C 2-6 )alkynyl, (C 3-8 )-cycloalkyl, phenyl optionally substituted with (C 1-4 )alkyl, (C 1-4 )alkyloxy, halogen, CN, CF 3 , OCF 3 or NO 2 , a 5- or 6-membered saturated heterocyclic group containing 1 or 2 heteroatoms selected from O and S, or a 5- or 6-membered heteroaryl group containing 1-3 heteroatoms selected from O, S and N optionally substituted with (C 1-4 )alkyl, (C 1-4 )-alkyloxy, halogen or CF 3 ; or R 1 is (C 1-3 )alkyl substituted with phenyl optionally substituted with (C 1-4 )alkyl, (C 1-4 )-alkyloxy, halogen or with 2 substituents at adjacent positions forming O—(CH 2 )n-O, wherein n is 1 or 2, a 5- or 6-membered heteroaryl group containing 1-3 heteroatoms selected from O, S and N optionally substituted with (C 1-3 )alkyl, (C 1-3 )alkyloxy or halogen, or a 5- or 6-membered saturated heterocyclic group containing 1 or 2 heteroatoms selected from O, S and N optionally substituted with (C 1-4 )alkyl, (C 1-4 )-alkyloxy, oxo, OH or halogen; or when X is NR 8 , R 1 may together with R 8 and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S and which ring is optionally substituted with OH, (C 1-4 )alkyl, (C 1-4 )alkyloxy or halogen; R 2 optionally represents 1-3 substituents independently selected from (C 1-4 )alkyl, (C 1-4 )-alkyloxy, CF 3 and halogen; R 3 optionally represents 1-4 substituents independently selected from (C 1-4 )alkyl and (C 1-4 )alkyl substituted by OH or 1 or more halogens; R 4 is H or (C 1-6 )alkyl; R 5 optionally represents 1-3 substituents independently selected from (C 1-3 )alkyl, (C 1-3 )alkyloxy and halogen; R 6 is H, (C 1-6 )alkyl optionally substituted with halogen, CF 3 or CN, (C 3-6 )cycloalkyl optionally containing a heteroatom selected from O and S, and optionally substituted by CN or phenyl, (C 3-6 )cycloalkyl(C 1-4 )alkyl, or a 5- or 6-membered (hetero)aryl group, optionally linked through a methylene group, and optionally substituted with (C 1-4 )alkyl, (C 1-4 )alkyloxy, (C 1-4 )alkylsulfonyl, halogen, CN, CF 3 , CF 3 O or NO 2 ; R 7 is H or (C 1-3 )alkyl; R 8 , when present, is H or (C 1-3 )alkyl; or R 8 together with R 1 , and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S and which ring is optionally substituted with OH, (C 1-3 )alkyl, (C 1-3 )alkyloxy or halogen; R 9 and R 10 are independently selected from H, (C 1-3 )alkyl or (C 1-3 )alkylcarbonyl; or R 9 and R 10 together with the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S; or a pharmaceutically acceptable salt thereof.